NantHealth Inc (NYSE:NH) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Several other equities research analysts have also recently issued reports on NH. Jefferies Group LLC reissued a “buy” rating and issued a $5.50 price objective (down from $8.00) on shares of NantHealth in a research report on Monday, June 19th. Canaccord Genuity reissued a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $8.55.

NantHealth (NH) traded down 1.07% during trading on Friday, reaching $4.63. 1,210,847 shares of the company were exchanged. The company’s 50-day moving average price is $4.46 and its 200-day moving average price is $5.81. The stock’s market capitalization is $564.61 million. NantHealth has a 1-year low of $4.00 and a 1-year high of $14.62.

NantHealth (NYSE:NH) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.32). The firm had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. NantHealth’s revenue for the quarter was down 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.15) earnings per share. On average, equities analysts forecast that NantHealth will post ($0.70) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/16/nanthealth-inc-nh-lifted-to-hold-at-bidaskclub.html.

A number of institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its position in NantHealth by 132.4% in the 2nd quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after buying an additional 18,000 shares during the period. State Street Corp boosted its position in NantHealth by 88.1% in the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock valued at $623,000 after buying an additional 68,963 shares during the period. Goldman Sachs Group Inc. boosted its position in NantHealth by 91.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock valued at $717,000 after buying an additional 81,024 shares during the period. Vanguard Group Inc. boosted its position in NantHealth by 20.2% in the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after buying an additional 71,087 shares during the period. Finally, Northern Trust Corp boosted its position in NantHealth by 133.9% in the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after buying an additional 86,955 shares during the period.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.